SUBSCRIBE
SUBSCRIBE

Phase III

Drug Development
Biopharma Industry News for March 26: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
March 26, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 25: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
March 25, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 24: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
March 24, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Novavax Shares Spike After Successful Late-Stage NanoFlu Vaccine Trial
The primary objectives were non-inferior immunogenicity of NanoFlu compared to Sanofi’s Fluzone Quadrivalent based on several 28-day metrics.
March 24, 2020
 · 
2 min read
 · 
Mark Terry
Drug Development
Eli Lilly Among Companies Pausing Some Clinical Trials Due to COVID-19 Pandemic
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
March 23, 2020
 · 
3 min read
 · 
Alex Keown
3d Illustration of Women Feeling Headache
Drug Development
Biohaven Pharma Plans to Move Vazegepant into Phase III for Acute Migraine Treatment
The company said the decision to advance the CGRP receptor antagonist into late-stage studies followed a successful end-of-phase meeting with the U.S. Food and Drug Administration.
March 23, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Industry News for March 23: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
March 23, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: March 16-20
Here’s a look at some of last week’s clinical trial news.
March 20, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Biopharma Industry News for March 20: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
March 20, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Grand Warszawski/Shutterstock
Drug Development
Roche Launches Phase III Study of Rheumatoid Arthritis Drug for COVID-19 Pneumonia
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
March 19, 2020
 · 
2 min read
 · 
Alex Keown
Load More
PRESS RELEASES
Press Releases
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 23, 2026
 · 
17 min read
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
 · 
7 min read
Press Releases
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 22, 2026
 · 
17 min read
Press Releases
IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia
January 21, 2026
 · 
5 min read
Press Releases
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
January 21, 2026
 · 
7 min read
Press Releases
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 21, 2026
 · 
5 min read
Press Releases
Tanabe Pharma America Announces Positive Topline Results for Dersimelagon in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
January 21, 2026
 · 
5 min read
Press Releases
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
January 20, 2026
 · 
5 min read
Press Releases
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
January 19, 2026
 · 
7 min read
Press Releases
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
13 min read
Press Releases
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 19, 2026
 · 
13 min read
Press Releases
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
9 min read
Press Releases
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
January 19, 2026
 · 
17 min read
Press Releases
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 16, 2026
 · 
6 min read
Press Releases
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 16, 2026
 · 
7 min read
Press Releases
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
January 15, 2026
 · 
34 min read
Press Releases
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly’s Olumiant®
January 15, 2026
 · 
5 min read
Press Releases
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
January 14, 2026
 · 
13 min read
Press Releases
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
January 14, 2026
 · 
9 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Load More